查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1830965

連續性腎臟替代療法市場

Continuous Renal Replacement Therapy Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

連續性腎臟替代療法市場預計將從 2024 年的 16.7 億美元擴大到 2031 年的 29.8 億美元。預計該市場在 2025 年至 2031 年期間的複合年成長率將達到 8.7%。市場洞察與分析師觀點：本報告概述了基於連續性腎臟替代療法市場當前趨勢的成長機會及其在預測期內的預期影響。

連續性腎臟替代療法 (CRRT) 是重度急性腎損傷 (AKI)、液體超負荷和尿毒症患者的關鍵治療方法，這些疾病可能導致危及生命的代謝紊亂。兒科 CRRT 設備需求的不斷成長以及導致腎臟疾病的慢性疾病的高發病率，正在推動連續性腎臟替代療法市場的成長。然而，重大不良腎臟事件 (MAKE) 的高風險對市場擴張構成了挑戰。

市場促進因素：導致腎臟疾病的慢性病高發生率全球每 10 人中就有 1 人患有慢性腎病 (CKD)，這是一種普遍且可能致命的疾病。 2015 年至 2019 年間，75% 的腎衰竭病例是由糖尿病和高血壓引起的。根據美國國家腎臟基金會 2020 年的估計，美國 20 歲以上的糖尿病患者中約有 30% 在其一生中面臨 CKD 的風險。此外，2020 年 CKD 造成的死亡人數超過了前列腺癌或乳腺癌，突顯了其作為一種未被充分認知的緊急衛生狀況。大約三分之一的美國成年人（約 8,000 萬人）面臨 CKD 的風險，CKD 現在被認為是 AKI 的重要危險因子。腎小球濾過率 (GFR) 降低和蛋白尿增加與 AKI 密切相關。

美國國立衛生研究院 (NIH) 報告稱，已開發國家急性腎損傷 (AKI) 的發生率正在上升，預計住院患者的盛行率將達到 15%，重症患者的盛行率甚至更高，達到 60%。全球住院病患的 AKI 發生率為 0.7% 至 31%，ICU 病患的盛行率則超過 50%。 3% 至 13% 的 AKI 患者需要腎臟替代療法 (RRT)，其中 40% 的患者估計需要接受 CRRT 治療超過 90 天。因此，導致腎臟疾病的慢性疾病的高盛行率顯著促進了持續性腎臟替代療法市場的成長。

然而，連續性腎臟替代療法 (CRRT) 存在一些副作用，例如低血壓、心搏過速和其他心律不整，這些副作用可能會對患者病情產生負面影響或阻礙復原。此外，CRRT 循環可能導致微量營養素、微量元素和/或治療藥物的快速清除，導致血液和組織中藥物濃度降低或不一致，從而引起副作用或降低治療效果。因此，這些副作用限制了連續性腎臟替代療法 (CRRT) 市場的成長。

策略洞察報告細分和範圍：透過檢查以下細分市場對連續性腎臟替代療法市場進行分析：產品、方式和最終用戶。

細分分析：持續性腎臟替代療法 (CRRT) 市場按產品分為透析液和置換液、一次性用品、血路套件和導管、CRRT 系統以及血液濾器。 CRRT 系統細分市場在 2022 年佔據最大市場佔有率，而血液濾網細分市場預計在 2022 年至 2030 年期間的複合年成長率最高。

依治療方式分類，連續性腎臟替代療法市場分為連續性靜脈-靜脈血液濾過 (CVVH)、連續性靜脈-靜脈血液透析濾過 (CVVHDF)、連續性靜脈-靜脈血液透析 (CVVHD) 和慢速連續超濾 (SCUF)。 CVVH 細分市場在 2022 年佔據最大市場佔有率，而 CVVHDF 細分市場預計將在 2022-2030 年期間實現最高複合年成長率。

按最終用戶分類，持續性腎臟替代治療市場可細分為醫院、門診護理中心、家庭護理和其他。 2022年，醫院護理領域佔據主導地位，但預計家庭監護領域在2022年至2030年期間的複合年成長率最高。

區域分析：連續性腎臟替代治療市場報告涵蓋北美（美國、加拿大和墨西哥）、歐洲（西班牙、英國、德國、法國、義大利和歐洲其他地區）、亞太地區（韓國、中國、印度、日本、澳洲和亞太其他地區）、中東和非洲（南非、沙烏地阿拉伯、阿拉伯聯合大公國和中東和非洲其他地區）以及南美洲和中美洲（巴西、阿根廷和南美洲和中美洲（巴西、阿根廷和南美洲和其他地區）。

就收入而言，北美在2022年引領了連續性腎臟替代療法市場。預計亞太市場將在2022年至2030年期間實現最高的複合年成長率，這得益於醫療基礎設施的改善和創新連續性腎臟替代治療（CRRT）技術的採用，而這些因素與醫療支出的成長息息相關。此外，市場參與者為提升其在亞太地區的影響力而採取的策略性舉措，例如與當地醫療機構建立合作夥伴關係，也支持了該地區市場的成長。

連續性腎臟替代療法市場報告範圍、競爭格局和主要公司：連續性腎臟替代療法市場報告重點關注百特國際公司、旭化成、費森尤斯醫療、Medica SpA、美敦力公司、貝朗、日機裝株式會社、東麗醫療株式會社、Infomed SA 和 Quanta Dialysis Technologies Inc. 等主要參與者。連續性腎臟替代療法市場的預測可以幫助利害關係人規劃其成長策略。這些公司正專注於推出新技術、改進現有產品並擴展業務，以滿足日益成長的全球消費者需求。

2022年4月，美國食品藥物管理局 (FDA) 批准百特國際公司 (Baxter International Inc.) 生產的 ST Set 用於連續性腎臟替代療法 (CRRT)。 ST Set 是一種預先連接的一次性體外循環迴路，透過半透膜進行血液淨化，設計用於 PrisMax 或 Prismaflex 控制裝置（監視器）。 2022年3月，領先的腎臟、血管和外科醫療產品製造商和供應商 Nipro Medical Corporation (Nipro) 宣佈在美國推出 SURDIAL DX 血液透析系統。 SURDIAL DX 是一款先進的血液透析系統，旨在為患者和臨床醫生提供最佳的透析治療體驗。該產品在日本製造，基於 Nipro 母公司 Nipro Corporation 超過 35 年的腎臟設備創新專業知識。

目錄

第1章：簡介

第2章：執行摘要

  • 關鍵見解
  • 市場吸引力分析

第3章：研究方法

第4章：連續性腎臟替代療法市場格局

  • 概述
  • PEST分析
  • 生態系分析
    • 價值鏈中的供應商列表

第5章：連續性腎臟替代療法市場－關鍵市場動態

  • 關鍵市場促進因素
  • 主要市場限制因素
  • 關鍵市場機會
  • 未來趨勢
  • 促進因素和限制因素的影響分析

第6章：連續性腎臟替代療法市場－全球市場分析

  • 連續性腎臟替代療法—全球市場概覽
  • 連續性腎臟替代療法－全球市場及2030年預測

第7章：連續性腎臟替代療法市場 - 收入分析 - 按產品，2020-2030 年

  • 概述
  • 透析液和置換液
  • 免洗用品
  • 血統套裝和試管
  • 血液濾器
  • CRRT系統

第 8 章：連續性腎臟替代療法市場 - 收入分析 - 按治療方式，2020-2030 年

  • 概述
  • 持續性靜脈-靜脈血液濾過（CVVH）
  • 持續性靜脈-靜脈血液透析濾過（CVVHDF）
  • 持續性靜脈-靜脈血液透析（CVVHD）
  • 慢速連續超濾（SCUF）

第9章：連續性腎臟替代療法市場-收入分析-按最終用戶，2020-2030

  • 概述
  • 醫院
  • 門診護理
  • 居家護理
  • 其他

第 10 章：連續性腎臟替代療法市場 - 收入分析，2020-2030 年 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 歐洲其他地區
  • 亞太
    • 澳洲
    • 中國
    • 印度
    • 日本
    • 韓國
    • 東南亞其他地區
  • 中東和非洲
    • 南非
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第 11 章：產業格局

  • 併購
  • 協議、合作、合資企業
  • 新產品發布
  • 擴張和其他策略發展

第 12 章：競爭格局

  • 關鍵參與者的熱圖分析
  • 公司定位與集中度

第 13 章：連續性腎臟替代療法市場 - 主要公司簡介

  • Baxter International Inc
  • Asahi Kasei
  • Fresenius Medical Care
  • Medica S.p.A.
  • Medtronic Plc
  • B. Braun
  • Nikkiso Co Ltd
  • Toray Medical Co Ltd
  • Infomed SA
  • Quanta Dialysis Technologies Inc

第 14 章：附錄

簡介目錄
Product Code: TIPHE100001251

The continuous renal replacement therapy market is expected to expand from US$ 1.67 billion in 2024 to US$ 2.98 billion by 2031. The market is projected to achieve a CAGR of 8.7% from 2025 to 2031.

Market Insights and Analyst View:This report outlines growth opportunities based on the current trends in the continuous renal replacement therapy market and their anticipated effects during the forecast period.

Continuous renal replacement therapy (CRRT) is a critical treatment for patients experiencing severe acute kidney injury (AKI), fluid overload, and uremia, which can lead to life-threatening metabolic disturbances. The rising demand for pediatric CRRT devices and the high incidence of chronic diseases that result in kidney disorders are driving the growth of the continuous renal replacement therapy market. However, the significant risk of major adverse kidney events (MAKE) poses a challenge to market expansion.

Market Drivers:High Prevalence of Chronic Diseases Leading to Kidney Disorders

Globally, 1 in 10 individuals is affected by chronic kidney disease (CKD), a prevalent and potentially fatal condition. Between 2015 and 2019, diabetes and hypertension were responsible for 75% of kidney failure cases. According to the National Kidney Foundation's 2020 estimates, approximately 30% of the diabetic population over 20 years old in the US is at risk of developing CKD during their lifetime. Furthermore, CKD caused more fatalities than prostate or breast cancer in 2020, highlighting its status as an under-recognized health emergency. About 1 in 3 American adults (around 80 million people) are at risk of CKD, which is now recognized as a significant risk factor for AKI. A decreased glomerular filtration rate (GFR) and increased proteinuria are closely linked to AKI.

The National Institute of Health reports a rising incidence of AKI in developed nations, with its prevalence among hospitalized patients expected to reach 15%, and even higher in critically ill patients at 60%. The global incidence of AKI in hospitalized patients ranges from 0.7% to 31%, with ICU patients experiencing rates exceeding 50%. Between 3% and 13% of AKI patients require renal replacement therapy (RRT), and 40% of these patients are estimated to need CRRT for over 90 days. Thus, the high prevalence of chronic diseases leading to kidney disorders significantly enhances the growth of the continuous renal replacement therapy market.

However, CRRT is associated with adverse effects such as hypotension, tachycardia, and other arrhythmias, which can negatively impact patient conditions or hinder recovery. Additionally, the CRRT circuit may lead to the rapid clearance of micronutrients, trace elements, and/or therapeutic drugs, resulting in low or inconsistent concentrations in blood and tissues, which can cause adverse effects or diminish therapeutic efficacy. Consequently, these adverse effects limit the growth of the continuous renal replacement therapy market.

Strategic Insights

Report Segmentation and Scope:The analysis of the continuous renal replacement therapy market has been conducted by examining the following segments: product, modality, and end user.

Segmental Analysis:The continuous renal replacement therapy market is categorized by product into dialysates and replacement fluids, disposables, bloodline sets and tubes, CRRT systems, and hemofilters. The CRRT systems segment held the largest market share in 2022, while the hemofilters segment is expected to exhibit the highest CAGR from 2022 to 2030.

By modality, the continuous renal replacement therapy market is divided into continuous venovenous hemofiltration (CVVH), continuous venovenous hemodiafiltration (CVVHDF), continuous venovenous hemodialysis (CVVHD), and slow continuous ultrafiltration (SCUF). The CVVH segment accounted for the largest market share in 2022, with the CVVHDF segment anticipated to achieve the highest CAGR during 2022-2030.

By end user, the continuous renal replacement therapy market is segmented into hospitals, ambulatory care centers, home care, and others. In 2022, the hospitals segment dominated the market share, but the home monitoring segment is projected to register the highest CAGR from 2022 to 2030.

Regional Analysis:The continuous renal replacement therapy market report covers North America (US, Canada, and Mexico), Europe (Spain, UK, Germany, France, Italy, and Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

In terms of revenue, North America led the continuous renal replacement therapy market in 2022. The Asia Pacific market is expected to register the highest CAGR from 2022 to 2030, driven by improvements in healthcare infrastructure and the adoption of innovative CRRT technologies, which are linked to increasing healthcare expenditures. Additionally, strategic initiatives by market players to enhance their presence in the Asia Pacific region, such as partnerships with local healthcare providers, support market growth in this area.

Continuous Renal Replacement Therapy Market Report Scope

Competitive Landscape and Key Companies:The continuous renal replacement therapy market report focuses on key players such as Baxter International Inc, Asahi Kasei, Fresenius Medical Care, Medica S.p.A., Medtronic Plc, B. Braun, Nikkiso Co Ltd, Toray Medical Co Ltd, Infomed SA, and Quanta Dialysis Technologies Inc. The forecast for the continuous renal replacement therapy market can assist stakeholders in planning their growth strategies. These companies are concentrating on launching new technologies, enhancing existing products, and expanding their operations to meet the increasing global consumer demand.

In April 2022, the US Food and Drug Administration (FDA) granted 510(k) clearance for the ST Set by Baxter International Inc. for use in continuous renal replacement therapy (CRRT). The ST Set is a pre-connected, disposable, extracorporeal circuit that facilitates blood purification through a semipermeable membrane, designed for use with the PrisMax or Prismaflex control units (monitors).

In March 2022, Nipro Medical Corporation (Nipro), a leading manufacturer and supplier of renal, vascular, and medical-surgical products, announced the commercial launch of the SURDIAL DX Hemodialysis System in the US. The SURDIAL DX is a cutting-edge hemodialysis system aimed at providing an optimal dialysis treatment experience for both patients and clinicians. Manufactured in Japan, this product is based on over 35 years of expertise in renal device innovation from Nipro's parent company, Nipro Corporation.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Continuous Renal Replacement Therapy Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Continuous Renal Replacement Therapy Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Continuous Renal Replacement Therapy Market - Global Market Analysis

  • 6.1 Continuous Renal Replacement Therapy - Global Market Overview
  • 6.2 Continuous Renal Replacement Therapy - Global Market and Forecast to 2030

7. Continuous Renal Replacement Therapy Market - Revenue Analysis (USD Million) - By Product, 2020-2030

  • 7.1 Overview
  • 7.2 Dialysates and Replacement Fluids
  • 7.3 Disposables
  • 7.4 Bloodline Sets and Tubes
  • 7.5 Hemofilters
  • 7.6 CRRT Systems

8. Continuous Renal Replacement Therapy Market - Revenue Analysis (USD Million) - By Modality, 2020-2030

  • 8.1 Overview
  • 8.2 Continuous venovenous hemofiltration (CVVH)
  • 8.3 Continuous venovenous hemodiafiltration (CVVHDF)
  • 8.4 Continuous venovenous hemodialysis (CVVHD)
  • 8.5 Slow continuous ultrafiltration (SCUF)

9. Continuous Renal Replacement Therapy Market - Revenue Analysis (USD Million) - By End User, 2020-2030

  • 9.1 Overview
  • 9.2 Hospital
  • 9.3 Ambulatory care
  • 9.4 Homecare
  • 9.5 Others

10. Continuous Renal Replacement Therapy Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America Continuous Renal Replacement Therapy Market Overview
    • 10.1.2 North America Continuous Renal Replacement Therapy Market Revenue and Forecasts to 2030
    • 10.1.3 North America Continuous Renal Replacement Therapy Market Revenue and Forecasts and Analysis - By Product
    • 10.1.4 North America Continuous Renal Replacement Therapy Market Revenue and Forecasts and Analysis - By Modality
    • 10.1.5 North America Continuous Renal Replacement Therapy Market Revenue and Forecasts and Analysis - By End User
    • 10.1.6 North America Continuous Renal Replacement Therapy Market Revenue and Forecasts and Analysis - By Countries
      • 10.1.6.1 United States Continuous Renal Replacement Therapy Market
        • 10.1.6.1.1 United States Continuous Renal Replacement Therapy Market, by Product
        • 10.1.6.1.2 United States Continuous Renal Replacement Therapy Market, by Modality
        • 10.1.6.1.3 United States Continuous Renal Replacement Therapy Market, by End User
      • 10.1.6.2 Canada Continuous Renal Replacement Therapy Market
        • 10.1.6.2.1 Canada Continuous Renal Replacement Therapy Market, by Product
        • 10.1.6.2.2 Canada Continuous Renal Replacement Therapy Market, by Modality
        • 10.1.6.2.3 Canada Continuous Renal Replacement Therapy Market, by End User
      • 10.1.6.3 Mexico Continuous Renal Replacement Therapy Market
        • 10.1.6.3.1 Mexico Continuous Renal Replacement Therapy Market, by Product
        • 10.1.6.3.2 Mexico Continuous Renal Replacement Therapy Market, by Modality
        • 10.1.6.3.3 Mexico Continuous Renal Replacement Therapy Market, by End User
  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 France
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 Australia
    • 10.3.2 China
    • 10.3.3 India
    • 10.3.4 Japan
    • 10.3.5 South Korea
    • 10.3.6 Rest of SouthEast Asia
  • 10.4 Middle East and Africa
    • 10.4.1 South Africa
    • 10.4.2 U.A.E
    • 10.4.3 Rest of Middle East and Africa
  • 10.5 South and Central America
    • 10.5.1 Brazil
    • 10.5.2 Argentina
    • 10.5.3 Rest of South and Central America

11. Industry Landscape

  • 11.1 Mergers and Acquisitions
  • 11.2 Agreements, Collaborations, Joint Ventures
  • 11.3 New Product Launches
  • 11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

  • 12.1 Heat Map Analysis by Key Players
  • 12.2 Company Positioning and Concentration

13. Continuous Renal Replacement Therapy Market - Key Company Profiles

  • 13.1 Baxter International Inc
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Asahi Kasei
  • 13.3 Fresenius Medical Care
  • 13.4 Medica S.p.A.
  • 13.5 Medtronic Plc
  • 13.6 B. Braun
  • 13.7 Nikkiso Co Ltd
  • 13.8 Toray Medical Co Ltd
  • 13.9 Infomed SA
  • 13.10 Quanta Dialysis Technologies Inc

14. Appendix

  • 14.1 Glossary
  • 14.2 About The Insight Partners
  • 14.3 Market Intelligence Cloud